As of Aug 31
| -0.28 / -3.11%|
The 1 analysts offering 12-month price forecasts for ZIOPHARM Oncology Inc have a median target of 10.00, with a high estimate of 10.00 and a low estimate of 10.00. The median estimate represents a +14.81% increase from the last price of 8.71.
The current consensus among 3 polled investment analysts is to Hold stock in ZIOPHARM Oncology Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.